Items Tagged ‘Refactory/Recurrent Prostate Cancer’

June 13th, 2016

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer

By

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. If prostate cancer recurs following initial […]

View full entry

Tags: Axumin, fluciclovine F 18, imaging, News, PET, Prostate Cancer, recurrence, Refactory/Recurrent Prostate Cancer, scan


February 22nd, 2016

Xtandi® Improves Survival in Advanced Prostate Cancer

By

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men […]

View full entry

Tags: bicalutamide, casodex, Early Stage I-II (A-B) Prostate Cancer, enzalutamide, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi


November 4th, 2015

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy

By

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical removal of the prostate (prostatectomy). Unfortunately, some patients will experience a cancer recurrence following surgery. Treatment […]

View full entry

Tags: anti-androgen therapy, ATT, clinical trial, News, Prostate Cancer, prostatectomy, radiation, recurrence, Refactory/Recurrent Prostate Cancer


February 23rd, 2015

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients

By

The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported in The Lancet Oncology and clear the way for a new treatment option for men with hormone refractory prostate cancer (HRPC).1 Prostate cancer is a […]

View full entry

Tags: abiraterone acetate, cancer, HRPC, Metastatic Stage IV (D) Prostate Cancer, new treatment option, News, prednisone, prostate, Prostate Cancer, Refactory/Recurrent Prostate Cancer, zytiga


November 6th, 2014

Xofigo Extends Survival in Hormone-Refractory Prostate Cancer

By

For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have not received Taxotere® (docetaxel), a chemotherapy drug that can be used in the treatment of advanced prostate cancer. These findings were recently published in The Lancet Oncology. Prostate cancer is a hormonally sensitive disease that […]

View full entry

Tags: Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, radium-223, Refactory/Recurrent Prostate Cancer, taxotere, xofigo


September 18th, 2014

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

By

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer […]

View full entry

Tags: castration-resistant prostate cancer, crpc, News, odm-201, Prostate Cancer, Refactory/Recurrent Prostate Cancer


September 15th, 2014

FDA Approves Use of Xtandi for Chemotherapy Naïve Men With Advanced Prostate Cancer

By

The FDA approved the use of Xtandi® (enzalutamide) in men who have not yet received chemotherapy, significantly expanding the potential patient population eligible to be treated with the oral medicine.  Xtandi originally gained U.S. approval in 2012 for use in patients with castration-resistant prostate cancer that has spread beyond the prostate only after they had […]

View full entry

Tags: enazlutamide, hormone refractory, metastatic prostate cancer, Metastatic Stage IV (D) Prostate Cancer, News, PREVAIL trial, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi


September 11th, 2014

New Survey Reveals that Prostate Cancer Impacts Sex Lives More than Any Other Aspect of Patients’ Lives

By

Washington, DC (September 8, 2014) – A recent survey conducted by ZERO – The End of Prostate Cancer and Ferring Pharmaceuticals Inc. aimed to uncover the impact of prostate cancer on patients, their caregivers, and the healthcare professionals (HCPs) that support them. The majority (64 percent) of patients surveyed report that their prostate cancer diagnosis […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, quality of life, Refactory/Recurrent Prostate Cancer


September 3rd, 2014

Cabozantinib Development in Prostate Cancer Halted

By

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal clinical trial.  Enrollment in a second, phase III study of cabozantinib in prostate cancer has also been halted based on the negative outcome from the first study. Prostate […]

View full entry

Tags: cabozantinib, hormone refractory, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


August 27th, 2014

Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer

By

Advaxis, Inc.a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in a Phase 1/2 study of patients with previously treated metastatic, castration-resistant prostate cancer. Both ADXS-PSA and pembrolizumab are investigational members of […]

View full entry

Tags: ADXS-PSA, Metastatic Stage IV (D) Prostate Cancer, News, pembrolizumab, Prostate Cancer, Refactory/Recurrent Prostate Cancer


June 18th, 2014

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer

By

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in metastatic prostate cancer patients who had been resistant to initial hormone therapy. Cells in the prostate gland have testosterone receptors and when […]

View full entry

Tags: hormone therapy, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi, zytiga


June 3rd, 2014

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients

By

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results were reported at the 2014 American Society of Clinical Oncology (ASCO) meeting held in Chicago. Prostate cancer occurs when the […]

View full entry

Tags: asco, docetaxel, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, taxotere


April 21st, 2014

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer

By

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm, Sweden. The targeted agent delayed the progression of metastatic disease, reduced the risk of death, and delayed the start of chemotherapy. The […]

View full entry

Tags: Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


February 27th, 2014

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer

By

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries, and, in those receiving radiotherapy, secondary malignancies. These results were published in The Lancet Oncology. The treatment of prostate cancer can cause lasting […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer


February 19th, 2014

Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer

By

Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 Genitourinary Cancers Symposium. The prostate is a male sex gland responsible for producing fluid that forms semen. It is located below the bladder, in front […]

View full entry

Tags: Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer